Action ISIS PHARMACEUTICALS, INC.
Ajouter à une liste
Instrument Inactif

Gouvernance ISIS Pharmaceuticals, Inc. Nasdaq

Actions

US4643301090

Recherche biotechnologique et médicale

Comité Exécutif: ISIS Pharmaceuticals, Inc.

Dirigeant
Fonctions occupéesDepuis
Brett Monia

Brett Monia

64 ans

Chief Executive Officer 01/01/2020
Founder 10/01/1989
Elizabeth Hougen

Elizabeth Hougen

64 ans

Director of Finance/CFO 01/05/2000
Darren Gonzales

Darren Gonzales

Comptroller/Controller/Auditor 01/01/2020
Matt Buck

Matt Buck

General Counsel 01/12/2005
Shannon Devers

Shannon Devers

56 ans

Human Resources Officer 01/04/2020
Dawn Henson

Dawn Henson

Sales & Marketing 01/03/2020
Tracy Berns

Tracy Berns

Compliance Officer -
Darcie Christopher

Darcie Christopher

Comptroller/Controller/Auditor 01/11/2024
Patrick O'Neil

Patrick O'Neil

52 ans

General Counsel 01/01/2013
Corporate Secretary -
C. Bennett

C. Bennett

69 ans

Chief Tech/Sci/R&D Officer 01/01/2020
Eugene Schneider

Eugene Schneider

54 ans

Chief Operating Officer 01/09/2023
Chief Tech/Sci/R&D Officer -
D. Walke

D. Walke

60 ans

Investor Relations Contact 01/01/2023
Kenneth Newman

Kenneth Newman

68 ans

Chief Tech/Sci/R&D Officer -
Sanjay Bhanot

Sanjay Bhanot

Chief Tech/Sci/R&D Officer 01/01/2000
Melissa Yoon

Melissa Yoon

General Counsel -
Parag Govil

Parag Govil

Chief Tech/Sci/R&D Officer 01/08/2024

Composition du Conseil d'Administration: ISIS Pharmaceuticals, Inc.

Administrateur
ComitésDepuis
Joseph Loscalzo

Joseph Loscalzo

74 ans

Governance Committee 02/06/2021
Nominating Committee 02/06/2021
Michael Hayden

Michael Hayden

74 ans

Audit Committee 01/10/2019
Governance Committee 01/10/2019
Nominating Committee 01/10/2019
Compensation Committee Chair 01/10/2019
Spencer Berthelsen

Spencer Berthelsen

73 ans

Governance Committee
Nominating Committee
Compensation Committee Chair 01/05/2002
Joan Herman

Joan Herman

72 ans

Compensation Committee 10/06/2019
HR Committee 25/01/2013
Audit Committee 10/06/2019
Joseph Klein

Joseph Klein

64 ans

Finance Committee
Audit Committee Chair 28/02/2011
Brett Monia

Brett Monia

64 ans

Audit Committee 01/10/2020
Compensation Committee 01/10/2020
Michael Yang

Michael Yang

64 ans

Compensation Committee Chair 10/10/2023
HR Committee Chair 09/06/2026
Allene Diaz

Allene Diaz

61 ans

Audit Committee 03/06/2021
Ludwig Hantson

Ludwig Hantson

63 ans

Director/Board Member 04/06/2026
Peter Reikes

Peter Reikes

65 ans

Director/Board Member 04/06/2026

Anciens Dirigeants et Administrateurs: ISIS Pharmaceuticals, Inc.

Insider
Fonctions occupées
DepuisJusqu'au
Joseph Wender
Joseph Wender
Director/Board Member 01/01/1994 04/06/2026
Independent Dir/Board Member 01/01/1994 04/06/2026
B. Parshall
B. Parshall
Director/Board Member 01/09/2000 04/06/2026
Chief Operating Officer 01/12/2007 15/01/2018
Corporate Secretary 01/11/1991 01/01/2015
Richard Geary
Richard Geary
Corporate Officer/Principal 01/08/2003 01/01/2026
Roslyn Patterson
Roslyn Patterson
Public Communications Contact 01/05/2018 01/02/2023
Sales & Marketing 01/05/2018 01/02/2023
Frederick Muto
Frederick Muto
Director/Board Member 01/03/2001 15/07/2022
Independent Dir/Board Member 01/03/2001 15/07/2022
Breaux Castleman
Breaux Castleman
Director/Board Member 25/06/2013 02/06/2021
Independent Dir/Board Member 25/06/2013 02/06/2021
Stanley Crooke
Stanley Crooke
Chief Executive Officer 10/01/1989 01/01/2020
Chairman 01/02/1991 02/06/2021
Founder 10/01/1989 02/06/2021
President 10/01/1989 01/05/1994
Damien McDevitt
Damien McDevitt
Corporate Officer/Principal 18/06/2018 01/09/2019
Sarah Boyce
Sarah Boyce
Corporate Officer/Principal 05/01/2015 01/04/2018
Joshua Patterson
Joshua Patterson
Director/Board Member 01/12/2006 01/03/2018
Corporate Officer/Principal 01/12/2006 01/03/2018
Amy Blackley
Amy Blackley
Public Communications Contact - 01/08/2016
Joseph Johnston
Joseph Johnston
General Counsel 01/01/2008 01/05/2016
Katherine Bishop
Katherine Bishop
Corporate Officer/Principal 01/01/2012 01/04/2015
Cynthia Nicholson
Cynthia Nicholson
Sales & Marketing 01/12/2013 -
John Reed
John Reed
Director/Board Member 01/02/2002 12/02/2013
Independent Dir/Board Member 01/02/2002 12/02/2013
Richard DiMarchi
Richard DiMarchi
Director/Board Member 01/12/2004 16/06/2011
Steven Hughes
Steven Hughes
Corporate Officer/Principal 01/01/2011 -
Mark K. Wedel
Mark K. Wedel
Chief Tech/Sci/R&D Officer 01/01/2001 18/08/2008
Jeff Jonas
Jeff Jonas
Corporate Officer/Principal 01/02/2007 21/07/2008
David J. Ecker
David J. Ecker
Founder 01/01/1989 -
Corporate Officer/Principal 01/01/1989 -
Kleanthis Xanthopoulos
Kleanthis Xanthopoulos
Corporate Officer/Principal 01/12/2007 -
Patrick Keran
Patrick Keran
Corporate Officer/Principal 01/04/2004 01/08/2006
Christopher F. O. Gabrieli
Christopher F. O. Gabrieli
Director/Board Member 01/01/1989 06/04/2006
Karen Potts
Karen Potts
General Counsel 01/03/2006 01/03/2006
Daniel Ripley
Daniel Ripley
Corporate Officer/Principal 01/01/2000 01/01/2006
Jeffrey Black
Jeffrey Black
Comptroller/Controller/Auditor 01/04/2005 01/04/2005
Jennifer Giottonini Cayer
Jennifer Giottonini Cayer
Corporate Officer/Principal 01/01/2004 01/03/2005
Ethel M. Koczon
Ethel M. Koczon
Chief Tech/Sci/R&D Officer 01/01/2005 01/01/2005
Neil Abdollahian
Neil Abdollahian
Corporate Officer/Principal 01/01/2004 01/01/2005
Jon T. Holmlund
Jon T. Holmlund
Corporate Officer/Principal 01/08/1997 01/03/2004
Douglas L. Cole
Douglas L. Cole
Chief Tech/Sci/R&D Officer 01/01/1991 01/01/2004
F. Andrew Dorr
F. Andrew Dorr
Chief Tech/Sci/R&D Officer 01/01/1996 01/01/2003
Muthiah Manoharan
Muthiah Manoharan
Corporate Officer/Principal 01/01/1990 01/01/2003
Ronald C. Griffith
Ronald C. Griffith
Corporate Officer/Principal 01/05/2001 01/12/2001
Richard K. Brown
Richard K. Brown
Corporate Officer/Principal 01/06/2001 -
Susan Knudson
Susan Knudson
Corporate Officer/Principal 01/04/2000 01/10/2000
William R. Shanahan
William R. Shanahan
Corporate Officer/Principal 01/10/1994 01/08/2000
Lisa R. Grillone
Lisa R. Grillone
Corporate Officer/Principal 01/01/1990 01/07/2000
Gary J. G. Atkinson
Gary J. G. Atkinson
Corporate Officer/Principal 01/01/1995 01/01/2000
Dan Kisner
Dan Kisner
Chief Operating Officer 01/01/1991 01/01/1999
President 01/01/1991 01/01/1999
John A. McNeil
John A. McNeil
Corporate Officer/Principal 01/10/1997 -
Edgardo Baracchini
Edgardo Baracchini
Corporate Officer/Principal 01/01/1992 01/01/1996
Arthur Levin
Arthur Levin
Corporate Officer/Principal 01/01/1995 -
Chris Mirabelli
Chris Mirabelli
Chief Tech/Sci/R&D Officer 01/01/1989 01/07/1993
Founder 01/01/1989 01/07/1993
Patricia Lowenstam
Patricia Lowenstam
Human Resources Officer 01/08/1992 -
Yasunori Kaneko
Yasunori Kaneko
Director of Finance/CFO 01/01/1991 01/01/1992
Nicholas M. Dean
Nicholas M. Dean
Corporate Officer/Principal 01/01/1991 -
Yun He
Yun He
Corporate Officer/Principal - -
Jon T. Holmlud
Jon T. Holmlud
Corporate Officer/Principal - -
Susan A. Gregory
Susan A. Gregory
Corporate Officer/Principal 12/08/2009 -
James G. Karras
James G. Karras
Director/Board Member 12/08/2009 -
Steven James
Steven James
Corporate Officer/Principal - -
Steven Schoenfeld
Steven Schoenfeld
Chief Tech/Sci/R&D Officer - -
Michael T. Love
Michael T. Love
Corporate Officer/Principal - -
Karen S. Lundstedt
Karen S. Lundstedt
Corporate Officer/Principal - -
Rosanne Crooke
Rosanne Crooke
Corporate Officer/Principal - -
Alan C. Mendelson
Alan C. Mendelson
Director/Board Member - -
Christopher McNulty
Christopher McNulty
Corporate Officer/Principal - -
Jay Tibor Novak
Jay Tibor Novak
Corporate Officer/Principal - -
Hans A. de Haan
Hans A. de Haan
Chief Tech/Sci/R&D Officer - 29/06/2009
Corporate Officer/Principal 29/06/2009 -
Shawn Swaney
Shawn Swaney
Corporate Officer/Principal - -
Bruce Turner
Bruce Turner
Corporate Officer/Principal - -
Mark B. Skaletsky
Mark B. Skaletsky
Director/Board Member - -
Kevin T. Skol
Kevin T. Skol
Corporate Officer/Principal 29/06/2009 -
Mark W. Lotz
Mark W. Lotz
General Counsel 13/07/2009 -
Corporate Officer/Principal - 13/07/2009
Kate Corcoran
Kate Corcoran
Corporate Officer/Principal - -
Cory Dunn
Cory Dunn
Corporate Officer/Principal - -
Amy D. Martini
Amy D. Martini
President - -
Aron F. Stein
Aron F. Stein
General Counsel - -
Lex M. Cowsert
Lex M. Cowsert
Corporate Officer/Principal - -
Anthony Altig
Anthony Altig
Comptroller/Controller/Auditor - -
Claudine Prowse
Claudine Prowse
Corporate Officer/Principal - -
Paul Cossum
Paul Cossum
Corporate Officer/Principal - -
Richard Lai Fatt
Richard Lai Fatt
Sales & Marketing - -
Kristina Lemonidis
Kristina Lemonidis
Public Communications Contact 29/06/2009 -
Kevin P. Anderson
Kevin P. Anderson
Corporate Officer/Principal - -
Maribel Gonzalez
Maribel Gonzalez
Comptroller/Controller/Auditor - -
Martin Peter Bedigian
Martin Peter Bedigian
Chief Tech/Sci/R&D Officer - -
Grantland E. Bryce
Grantland E. Bryce
General Counsel - -
Gregory R. Wade
Gregory R. Wade
Corporate Officer/Principal - -
K. Lea Sewell
K. Lea Sewell
Corporate Officer/Principal - -
Kale Ruby
Kale Ruby
Corporate Officer/Principal - -
Drusilla Scott
Drusilla Scott
Corporate Officer/Principal - -
Aron Stern
Aron Stern
Chief Administrative Officer 06/03/2013 -
Director of Finance/CFO 06/03/2013 -

Distribution de l'Âge des Dirigeants

Parité Homme Femme

Homme26
Femme11

Dont comité exécutif

Homme10
Femme6

Dont Administrateurs

Homme8
Femme2

Profil Société

Logo ISIS Pharmaceuticals, Inc.
Ionis Pharmaceuticals, Inc. développe six médicaments commercialisés destinés au traitement de maladies graves, notamment des médicaments pour les maladies neurologiques et cardiovasculaires. Ses médicaments commercialisés comprennent TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) et WAYLIVRA (volanesorsen). TRYNGOLZA réduit les taux de triglycérides chez les adultes atteints du syndrome de chylomicronémie familiale (FCS). WAINUA est autorisé pour le traitement de la polyneuropathie associée à l’amylose héréditaire à transthyrétine (ATTRv-PN) chez l’adulte. SPINRAZA est utilisé pour le traitement des patients pédiatriques et adultes atteints d’amyotrophie spinale. QALSODY est approuvé pour le traitement de la sclérose latérale amyotrophique chez les adultes présentant une mutation du gène de la superoxyde dismutase 1 (SOD1), ou SOD1-ALS. TEGSEDI est approuvé pour le traitement de l’ATTRv-PN chez les adultes. WAYLIVRA est approuvé en complément d’un régime alimentaire chez les patients adultes atteints d’un FCS confirmé génétiquement et présentant un risque élevé de pancréatite aiguë potentiellement mortelle.
Employés
-
Secteur
Recherche biotechnologique et médicale
Agenda
29/07 Publication des résultats - Q2 2026
Plus d'informations sur la société

Départs de Personnes Clées

Stanley Crooke
-
Stanley Crooke

Chief Executive Officer

10/01/1989 01/01/2020

  1. Bourse
  2. Actions
  3. Action IONS
  4. Action
  5. Société ISIS Pharmaceuticals, Inc.
  6. Gouvernance

Sélectionnez votre édition

Toutes les informations financières adaptées au niveau national

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong